HIPO
Hippo Holdings Inc.
HIPO's outlook is improving, though it still trails on the overall score.
JPM
JPMorgan Chase & Co.
JPM has the edge over HIPO overall, supported by lower modeled downside and stronger modeled upside.
HIPO Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Stable | |
| N/A | |
| N/A |
HIPO's revenue is currently strong, and its profitability is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like HIPO.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
HIPO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.3x | $8.14 | -78% |
| Fair | 7.7x | $9.87 | -73% |
| Expensive | 11x | $14.71 | -60% |
| Forward | 23x | $36.96 | — |
| Current | 29x | $36.96 | — |
Historical ranges are pointers, not guarantees.
HIPO's PE is in its expensive range at 29x. If earnings grow as analysts expect, today's price would be 23x next year's earnings.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM has the edge over HIPO in the historical PE scenario, which offers more potential upside but is not a forecast.
HIPO Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
HIPO has the edge over JPM on the outlook, with more favorable valuation expectations.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for JPM, with profitability improving.
HIPO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.58 | +23% |
| Q3 2026 | $1.29 | -65% |
| Q2 2026 | $4.73 | +$5.12 |
| Q1 2026 | $4.40 | +$6.48 |
| Q4 2025 | $2.22 | +$3.86 |
| Q3 2025 | $3.72 | +$8.89 |
| Q2 2025 | -$0.39 | +$6.68 |
| Q1 2025 | -$2.08 | +$7.96 |
| Q4 2024 | -$1.64 | +$9.94 |
HIPO earned $1.29 per share over the past year, down 65% from the year before.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM has the edge over HIPO on earnings, with more consistent year-over-year improvement.
HIPO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $156M | +29% |
| Q2 2026 | $144.7M | +23% |
| Q1 2026 | $121.5M | +10% |
| Q4 2025 | $120.4M | +18% |
| Q3 2025 | $120.6M | +26% |
| Q2 2025 | $117.3M | +31% |
| Q1 2025 | $110.3M | +30% |
| Q4 2024 | $101.9M | +58% |
HIPO has the edge over JPM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.7% | -76 points |
| Q2 2026 | 7.6% | +4.2 points |
| Q1 2026 | 5.9% | +47 points |
| Q4 2025 | 5.7% | -41 points |
| Q3 2025 | 81% | +87 points |
| Q2 2025 | 3.4% | +44 points |
| Q1 2025 | -41% | -2.7 points |
| Q4 2024 | 46% | +107 points |
HIPO's operating margin was 5.7% last quarter, down 76 points from the same quarter a year ago.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM's revenue has grown year over year for five quarters in a row: $50.2B last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM has the edge over HIPO on profitability, with a higher operating margin.
HIPO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $72.2M | +330% |
| Q2 2026 | $43M | +73% |
| Q1 2026 | $8.4M | +$44.1M |
| Q4 2025 | $3.2M | +$9.7M |
| Q2 2025 | $24.8M | +$35.5M |
| Q1 2025 | -$35.7M | -303% |
| Q4 2024 | -$6.5M | +$42.4M |
| Q2 2024 | -$10.7M | +$27.6M |
HIPO has the edge over JPM on cash generation, producing positive trailing cash flow while its opponent burns cash.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM's free cash flow was −$84.2B over the past year, against −$120B the year before. Free cash flow isn't a meaningful measure for financial services companies like JPM.
HIPO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.8% | +478K shares |
| 1 year | +3.9% | +1M shares |
| 3 years | +14% | +3.3M shares |
| 5 years | +21% | +4.7M shares |
| Available history | +5479% | +26.5M shares |
HIPO has 27M diluted shares, up 3.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q4 2024 | $15.6M |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | $1.6M |
| Q1 2023 | $200,000 |
JPM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -11.2M shares |
| 1 year | -3.1% | -84.6M shares |
| 3 years | -8.5% | -249M shares |
| 5 years | -11% | -322M shares |
| Available history | -17% | -547M shares |
JPM has the edge over HIPO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1B |
| Q2 2026 | $6.8B |
| Q1 2026 | $8.3B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.3B |
| Q2 2025 | $7.5B |
| Q1 2025 | $7.5B |
| Q4 2024 | $4.3B |
JPM spent $24.5B buying back its own shares over the past year, down 11% from the year before.
HIPO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2025 | -8.7x | Net Cash |
HIPO has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like HIPO.
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like JPM.
HIPO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.3 | Neutral |
| Stochastic | 68.3 | Neutral |
HIPO's weekly RSI is 63 (neutral) and its Stochastic is 68 (neutral).
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
HIPO PE vs Financial Services Sector
| Metric | HIPO | Sector median | Relative |
|---|---|---|---|
| PE | 29x | 13x | 120% above |
| PE % | 100 | 62 | 38 pts above |
HIPO is trading at 29x earnings, a 120% premium to the Financial Services sector's median of 13x.
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM has the edge over HIPO on valuation relative to its sector.
HIPO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $34.9 | 6% above |
| 20 week MA | $32.7 | 13% above |
| 50 week MA | $29.9 | 24% above |
| 100 week MA | $29.4 | 26% above |
| 200 week MA | $22.6 | 63% above |
HIPO has the edge over JPM on trend strength, trading above more of its moving averages.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
JPM's trend is mixed: it's above four of its five weekly moving averages, and 45% above its 200-week average.
HIPO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $296.3 | $77.3 | -74% |
| 2022 | $77.3 | $12.1 | -84% |
| 2023 | $12.1 | $9.12 | -25% |
| 2024 | $9.12 | $27.4 | +200% |
| 2025 | $27.4 | $31.3 | +14% |
| 2026 YTD | $31.3 | $37.0 | +18% |
HIPO has the edge over JPM on returns for 2026, with the stronger performance.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has finished higher in four of the last six years. It's up 4.5% so far in 2026.